# Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension

> **NCT04859582** · PHASE3 · WITHDRAWN · sponsor: **Merck Sharp & Dohme LLC**

## Conditions studied

- Stomach Neoplasms

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Cisplatin
- **DRUG:** 5-fluorouracil
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **DRUG:** Placebo for Pembrolizumab

## Key facts

- **NCT ID:** NCT04859582
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-11-08
- **Primary completion:** 2024-11-29
- **Final completion:** 2024-11-29
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawn due to protocol amendment
- **Last updated:** 2021-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04859582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04859582, "Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04859582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*